Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand

Kai Yang,Shunyao Li,Tianqi Wang,Xueming Yan,Qian He,Ruonan Ning,Xing Xu,Wei Yao,Xiaofei Zhang,Chunhao Yang,Min Jiang,Lianfu Deng
DOI: https://doi.org/10.1021/acs.jmedchem.2c00081
IF: 8.039
2022-08-13
Journal of Medicinal Chemistry
Abstract:Receptor activator of nuclear factor-κB (RANK) and its ligand, RANKL, play pivotal roles in bone remodeling. The monoclonal antibody denosumab successfully inhibited the maturation of osteoclasts (OCs) by binding to RANKL in the clinic. We continued our efforts to develop small-molecule inhibitors of RANKL. In this work, 41 β-carboline derivatives were synthesized based on previously synthesized compound Y1599 to improve its drug-like properties. Compound Y1693 was identified as a potent RANKL...
chemistry, medicinal
What problem does this paper attempt to address?